Capitalizing Life Science Innovations

PITTSBURGH, Sept. 28, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, announced today that Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase, will participate in a fireside chat at the virtual Chardan 5th Annual Genetic Medicines Conference being held October 4 - 5.

Chardan 5th Annual Genetic Medicines Conference
Date: Tuesday, October 5th
Time: 11:30 a.m. ET
Location: Webcast link or at the company’s website


About NeuBase Therapeutics, Inc. 
NeuBase is accelerating the genetic revolution by developing a new class of precision genetic medicines which can be designed to increase, decrease, or change gene function, as appropriate, to resolve genetic defects that drive disease. NeuBase’s targeted PATrOL™ therapies are centered around its proprietary drug scaffold to address genetic diseases at the DNA or RNA level by combining the highly targeted approach of traditional genetic therapies with the broad organ distribution capabilities of small molecules. With an initial focus on silencing disease-causing mutations in debilitating neurological, neuromuscular, and oncologic disorders, NeuBase is committed to redefining medicine for the millions of patients with both common and rare conditions. To learn more, visit

NeuBase Investor Contact:
Daniel Ferry
LifeSci Advisors, LLC
+1 (617) 430-7576
This email address is being protected from spambots. You need JavaScript enabled to view it.

NeuBase Media Contact:
Jessica Yingling, Ph.D.
Little Dog Communications Inc.
+1 (858) 344-8091
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Zyversa Logo

Source: NeuBase Therapeutics, Inc.